mRNA Victoria and BioMelbourne Network, are hosting a series of four lectures in the first half of 2023 for the Victorian RNA community.A networking session for attendees to foster new connections and nurture existing ones with each other will conclude each lecture event. Refreshments will be provided.These lectures present an opportunity for leading specialists in the RNA sector to share their knowledge with the local RNA community. The accompanying networking session following each lecture is also an opportunity to foster connections between researchers, industry and government so that synergies and collaboration opportunities can be discovered.
Lecture Two: Fireside Chat with Professor Robert Langer, Co-Founder of Moderna, Institute Professor at MIT
Professor Robert Langer will be joining us live from Boston.Professor Robert Langer is an American chemical engineer and Co-Founder of Moderna. He is one of twelve Institute Professors at the Massachusetts Institute of Technology, holds over 1,400 granted or pending patents and is one of the most highly cited researchers in the world.During this fireside chat, Professor Langer will be dialling in live from Boston to speak about his career, share lessons he learnt along the way, and participate in Q&A facilitated by Professor Christopher Porter, Director of the Monash Institute of Pharmaceutical Sciences
Lecture Two event recording:
0.03 Welcome and opening remarks | Jeff Malone, CEO, BioMelbourne Network
4:27 Lecture 2 Introduction | Professor Chris Porter, Director, Monash Institute of Pharmaceutical Sciences, Monash University
9:41 Professor Robert Langer addresses audience (live streamed from Boston)
31:25 Fireside chat with Professor Robert Langer, facilitated by Professor Chris Porter
53:45 Audience Q&A
About mRNA Victoria
mRNA Victoria is responsible for leading the Victorian Government’s commitment to establish a world-class mRNA and RNA industry in Victoria, by supporting supply chain, research and development for pre and clinical research, commercialisation and manufacturing investments.Its role is to identify key capabilities, gaps, opportunities and lead the Victorian Government’s engagement, investment and partnerships with domestic and international companies, researchers and stakeholders to build RNA capability.
Professor Chris Porter Director, Monash Institute of Pharmaceutical Sciences Monash University
Chris Porter is Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University. MIPS houses over 450 researchers and graduate students across five major themes of activity in Pharmaceutical Sciences – Drug Discovery Biology, Medicinal Chemistry, Drug Candidate Optimisation, Drug Delivery, Disposition and Dynamics and Medicine Use and Safety. Therapeutically, MIPS strengths lie in neuroscience and mental health, cardiovascular and metabolic health, and global health. Major capabilities lie in G-protein coupled receptor (GPCR) biology, synthetic medicinal chemistry, fragment-based drug design, ADME-informed lead optimisation, drug formulation and delivery (including nanomedicine), and optimised medicine use and safety in community and clinical settings. MIPS is committed to research translation and industry engagement and recent successes include the spin out/start-up companies Cincera, Septerna, Ankere and Inosi and significant ongoing relationships with local and international companies including eg. J+J, Takeda, Servier, CSL, Starpharma, PureTech and Polyactiva.
Professor Robert Langer (USA) Co-Founder, Moderna Institute Professor, Massachusetts Institute of Technology (MIT)
Robert Langer is one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member.
He has written over 1,500 articles, which have been cited over 381,000 times; his h-index of 307 is the highest of any engineer in history and the 2nd highest of any individual in any field. His patents have licensed or sublicensed to over 400 companies; he is a cofounder of a number of companies including Moderna. Dr Langer served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002.
Robert has over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of 3 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, Hoover Medal, Dreyfus Prize in Chemical Sciences, BBVA Frontiers of Knowledge Award in Biomedicine, and the Balzan Prize.
He holds 40 honorary doctorates, including Harvard, Yale, Columbia, and Northwestern, and has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.
BioMelbourne Network respectfully acknowledges the Traditional Custodians of the unceded lands and waters of Victoria, the Bunurong, Eastern Maar, Gunaikurnai, Wadawurrung and Wurundjeri Woi-wurrung peoples, on which BioMelbourne Network lives and works. We pay respect to their Elders past and present. We acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector.
We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.